PMID- 32483450
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20240328
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 10
IP  - 14
DP  - 2020
TI  - Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related 
      immune cells migration.
PG  - 6231-6244
LID - 10.7150/thno.45219 [doi]
AB  - During the last few decades, cell-based anti-tumor immunotherapy emerged and it 
      has provided us with a large amount of knowledge. Upon chemokines recognition, 
      immune cells undergo rapid trafficking and activation in disease milieu, with 
      immune cells chemotaxis being accompanied by activation of diverse intercellular 
      signal transduction pathways. The outcome of chemokines-mediated immune cells 
      chemotaxis interacts with the cue of mammalian target of rapamycin (mTOR) in the 
      tumor microenvironment (TME). Indeed, the mTOR cascade in immune cells involves 
      migration and infiltration. In this review, we summarize the available 
      mTOR-related chemokines, as well as the characterized upstream regulators and 
      downstream targets in immune cells chemotaxis and assign potential underlying 
      mechanisms in each evaluated chemokine. Specifically, we focus on the involvement 
      of mTOR in chemokine-mediated immune related cells in the balance between tumor 
      immunity and malignancy.
CI  - (c) The author(s).
FAU - Jin, Jing
AU  - Jin J
AD  - Department of Oncology, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, Sichuan 646000, P.R. China.
FAU - Zhao, Qijie
AU  - Zhao Q
AD  - Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou, 
      646000, Sichuan, PR China.
AD  - Department of Pathophysiology, College of Basic Medical Science, Southwest 
      Medical University, Luzhou, 646000, Sichuan, PR China.
AD  - South Sichuan Institute of Translational Medicine, Luzhou, 646000, Sichuan, PR 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200515
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Chemokines)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Cell Movement/*immunology
MH  - Chemokines/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy
MH  - Neoplasms/*immunology/metabolism/pathology/therapy
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*immunology/metabolism
MH  - Tumor Microenvironment/immunology
PMC - PMC7255024
OTO - NOTNLM
OT  - Chemokine
OT  - Chemotaxis
OT  - Immune cells
OT  - Tumor microenvironment (TME)
OT  - mTOR
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/06/03 06:00
MHDA- 2021/05/19 06:00
PMCR- 2020/01/01
CRDT- 2020/06/03 06:00
PHST- 2020/02/23 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - thnov10p6231 [pii]
AID - 10.7150/thno.45219 [doi]
PST - epublish
SO  - Theranostics. 2020 May 15;10(14):6231-6244. doi: 10.7150/thno.45219. eCollection 
      2020.